Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 5/20 | 0.57 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.56 |
| ▸ | FPR2 | P25090 | 2/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5489495 | 1.00 | PSMB5 (0.62) | PSMB5TSHRACEGPR34FPR2 | |
| SCHEMBL21583769 | 0.89 | ALDH1A1 (0.65) | PSMB5L3MBTL1 | |
| SCHEMBL21583766 | 0.89 | ALDH1A1 (0.65) | PSMB5L3MBTL1 | |
| SCHEMBL20798175 | 0.87 | L3MBTL1 (0.52) | PSMB5ACEGPR34FPR2MME | |
| SCHEMBL20798174 | 0.87 | L3MBTL1 (0.52) | PSMB5ACEGPR34FPR2MME | |
| SCHEMBL11036712 | 0.86 | L3MBTL1 (0.51) | PSMB5ACEGPR34FPR2MME | |
| SCHEMBL23201777 | 0.85 | PSMB5 (0.63) | PSMB5ACEFPR2L3MBTL1 | |
| SCHEMBL21583746 | 0.85 | PSMB5 (0.63) | PSMB5ACEFPR2L3MBTL1 | |
| SCHEMBL9417473 | 0.83 | GPR34 (0.62) | ACEGPR34MMENPSR1 | |
| SCHEMBL7296506 | 0.83 | GPR34 (0.73) | PSMB5GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3805237-B1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | JIANGSU CHUANGTE PHARMACEUTICAL TECH CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| EP-3805237-A1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| EP-3805237-A1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019228299-A1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | 江苏正大丰海制药有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | disclosed |
| US-8003658-B2 | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-23 | — | — | US | disclosed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | SEM1, VIP, PSMB11 | PSMB5 38/4885TSHR 2413/4885ACE 137/4885 |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PSMB5 3897/4885TSHR 4537/4885ACE 1439/4885 |
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | SEM1, VIP, PSMB11 | PSMB5 38/4885TSHR 2413/4885ACE 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.